Literature DB >> 29282357

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

S Cerquozzi1, D Barraco2, T Lasho2, C Finke2, C A Hanson3, R P Ketterling3, A Pardanani2, N Gangat2, A Tefferi4.   

Abstract

In a recent International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) study, prior arterial events and hypertension were predictors of subsequent arterial thrombosis whereas prior venous events and age ≥65 years predicted venous thrombosis in polycythemia vera (PV). In the current study, we sought to validate the above findings and identify additional predictors of arterial versus venous thrombosis. At a median follow up of 109 months, thrombosis after diagnosis occurred in 128 (22%) patients; 82 (14%) arterial and 57 (10%) venous events. On multivariate analysis, prior arterial events (<0.0001), hyperlipidemia (p = 0.03), and hypertension (p = 0.02) predicted subsequent arterial events. In comparison, prior venous events (p = 0.05), leukocytosis ≥11 × 109/L (p = 0.002), and major hemorrhage (p = 0.02) were predictors of subsequent venous events. Salient associations with arterial thrombosis included age ≥ 60 years, hypertension, diabetes, hyperlipidemia and normal karyotype whereas age ≤ 60 years, females, palpable splenomegaly and history of major hemorrhage were associated with venous thrombosis. TET2 or ASXL1 mutations did not impact arterial nor venous thrombosis. In conclusion, we identify distinct associations for arterial versus venous thrombosis in PV and confirm that a prior arterial or venous thrombotic event is the most reliable predictor of subsequent events.

Entities:  

Mesh:

Year:  2017        PMID: 29282357      PMCID: PMC5802551          DOI: 10.1038/s41408-017-0035-6

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   11.037


  15 in total

1.  Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience.

Authors:  Mahnur Haider; Naseema Gangat; Curtis Hanson; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-04-06       Impact factor: 10.047

2.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

Authors:  Alessandra Carobbio; Juergen Thiele; Francesco Passamonti; Elisa Rumi; Marco Ruggeri; Francesco Rodeghiero; Maria Luigia Randi; Irene Bertozzi; Alessandro M Vannucchi; Elisabetta Antonioli; Heinz Gisslinger; Veronika Buxhofer-Ausch; Guido Finazzi; Naseema Gangat; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

Review 3.  Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition.

Authors:  A Simons; L G Shaffer; R J Hastings
Journal:  Cytogenet Genome Res       Date:  2013       Impact factor: 1.636

4.  In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Authors:  Tiziano Barbui; Alessandra Carobbio; Elisa Rumi; Guido Finazzi; Heinz Gisslinger; Francesco Rodeghiero; Maria Luigia Randi; Alessandro Rambaldi; Bettina Gisslinger; Lisa Pieri; Irene Bertozzi; Ilaria Casetti; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood       Date:  2014-11-06       Impact factor: 22.113

5.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 6.  Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Authors:  Ayalew Tefferi; Tiziano Barbui
Journal:  Am J Hematol       Date:  2015-02       Impact factor: 10.047

7.  Cardiovascular events and intensity of treatment in polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

Authors:  Alexandra P Wolanskyj; Susan M Schwager; Rebecca F McClure; Dirk R Larson; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2006-02       Impact factor: 7.616

10.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

View more
  29 in total

1.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

Review 2.  Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors:  Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

3.  Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study.

Authors:  Yoko Edahiro; Tomoki Ito; Akihiko Gotoh; Mika Nakamae; Fumihiko Kimura; Michiaki Koike; Keita Kirito; Hideho Wada; Kensuke Usuki; Takayuki Tanaka; Takehiko Mori; Satoshi Wakita; Toshiki I Saito; Akiko Kada; Akiko M Saito; Kazuya Shimoda; Yuka Sugimoto; Toshiro Kurokawa; Akihiro Tomita; Yoshinori Hashimoto; Koichi Akashi; Itaru Matsumura; Katsuto Takenaka; Norio Komatsu
Journal:  Int J Hematol       Date:  2022-07-09       Impact factor: 2.319

Review 4.  Hematocrit, White Blood Cells, and Thrombotic Events in the Veteran Population With Polycythemia Vera.

Authors:  Tsewang Tashi
Journal:  Fed Pract       Date:  2022-03-16

5.  JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Authors:  Zuzanna Kanduła; Michał Janowski; Barbara Więckowska; Edyta Paczkowska; Krzysztof Lewandowski
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-15       Impact factor: 4.322

6.  Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.

Authors:  Ana Triguero; Alexandra Pedraza; Manuel Pérez-Encinas; María Isabel Mata-Vázquez; Patricia Vélez; Laura Fox; Montse Gómez-Calafat; Regina García-Delgado; Mercedes Gasior; Francisca Ferrer-Marín; Valentín García-Gutiérrez; Anna Angona; María Teresa Gómez-Casares; Beatriz Cuevas; Clara Martínez; Raúl Pérez; José María Raya; Lucía Guerrero; Ilda Murillo; Beatriz Bellosillo; Juan Carlos Hernández-Boluda; Cristina Sanz; Alberto Álvarez-Larrán
Journal:  Ann Hematol       Date:  2022-08-30       Impact factor: 4.030

Review 7.  Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.

Authors:  Ivan Krecak; Marko Lucijanic; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

Review 8.  Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.

Authors:  Alison R Moliterno; Yelena Z Ginzburg; Ronald Hoffman
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

9.  The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.

Authors:  Mohamed Hussam Aswad; Jarmila Kissova; Petra Ovesna; Lucie Rihova; Miroslav Penka
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 10.  Inflammation, Infection and Venous Thromboembolism.

Authors:  Meaghan E Colling; Benjamin E Tourdot; Yogendra Kanthi
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.